At the Benzinga Virtual Healthcare Summit, Adam Mendelsohn, Ph.D., co-founder and CEO of Vivani Medical, discussed the company’s innovative approach to chronic disease treatment through miniature implantable devices.

These devices are designed to release therapeutic levels of medicine over several months, addressing the widespread issue of medication non-adherence.

New Approach To Medication Delivery

Vivani Medical’s technology aims to improve the translation of clinical results to real-world effectiveness by ensuring consistent medication delivery. “About half of people don’t take medicine as prescribed in the real world,” Mendelsohn noted, highlighting the gap the company seeks to bridge with its implantable solution.

Breakthrough In Weight Loss Treatment

Mendelsohn also shared recent advancements in the company’s preclinical weight loss data for the NPM-115 device. The device showed promising results in obese mice models, with weight loss outcomes comparable to existing therapies.

“The weight loss was about 20% from our implant and was also about 20% with the semaglutide injections,” Mendelsohn explained, indicating the potential effectiveness of the NPM-115 device in human treatments

See Also: How Are Obesity Drugs And Nvidia Related? Success Of Ozempic, Wegovy Propels Novo Nordisk Foundation To Fund Nvidia-Powered AI Supercomputer For Faster Drug Development

Addressing Medication Adherence Challenges

The discussion further delved into the challenges of medication adherence, particularly in the context of GLP-1 treatments for weight loss and type 2 diabetes. Mendelsohn emphasized the unique position of Vivani Medical’s implantable device in addressing these challenges by providing a steady and controlled release of medication. This approach aims to mitigate common side effects and improve patient compliance.

Vivani Medical’s development of the NPM-115 device represents a significant step forward in the treatment of chronic diseases. It has the potential to enhance patient outcomes through improved medication adherence and a more convenient treatment regimen. As the company moves towards human testing, the healthcare community watches closely for the impact this technology could have on chronic disease care.

Benzinga Cannabis Capital Conference is coming to Florida

The Benzinga Cannabis Capital Conference is returning to Florida in a new venue in Hollywood on April 16 and 17, 2024. The two-day event at The Diplomat Beach Resort will be a chance for entrepreneurs, both large and small, to network, learn, and grow.

Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars – this conference is the go-to event of the year for the cannabis world. Get your tickets now on bzcannabis.com – Prices will increase very soon!

Read Next: Is Eli Lilly Winning The War On Weight Loss Drugs? Zepbound Overtakes Wegovy In US Prescriptions

Photo: Shutterstock